Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
WALTHAM, Mass., June 29, 2017 -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to support the Ovarian Cancer Research Fund Alliance (OCRFA) as the Presenting Sponsor of the 2017 Ovarian Cancer National Conference, being held July 7-9 in Chicago, IL. The OCRFA National Conference is the largest and longest-running conference for women living with ovarian cancer and their caregivers, bringing together more than 400 survivors, caregivers, researchers, and advocates to hear about the latest innovations in ovarian cancer, find hope and inspiration, and support ovarian cancer awareness initiatives.
“Our annual conference is an opportunity to provide much needed education on cutting-edge developments in diagnosis, treatment and quality of life to women with ovarian cancer and their caregivers,” said Audra Moran, President & CEO of Ovarian Cancer Research Fund Alliance. “We are excited to partner with TESARO on our flagship conference and look forward to continued collaboration in the future.”
“Driven by a deep appreciation for patient needs, TESARO is committed to not only supporting, but truly partnering with women living with ovarian cancer,” said Lonnie Moulder, CEO of TESARO. “Patients are at the center of all that we do, and we are thrilled to join forces with OCRFA to support the 2017 Ovarian Cancer National Conference and be a part of this life-changing experience for survivors and caregivers.”
For more information about the Ovarian Cancer National Conference, please visit https://conference.ocrfa.org.
About TESARO
TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.
Investor/Media Contact: Jennifer Davis Vice President, Corporate Affairs & Investor Relations +1.781.325.1116 or [email protected]
